+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Pembrolizumab"

From
From
From
Keytruda (pembrolizumab; Merck & Co) Drug Overview 2019 - Product Thumbnail Image

Keytruda (pembrolizumab; Merck & Co) Drug Overview 2019

  • Drug Pipelines
  • September 2019
  • 141 Pages
  • Global
From
Disease Analysis: Head and Neck Cancer - Product Thumbnail Image

Disease Analysis: Head and Neck Cancer

  • Report
  • March 2021
  • 77 Pages
  • Global
Wilms Tumor Protein (WT33 or WT1) - Pipeline Review, H2 2019 - Product Thumbnail Image

Wilms Tumor Protein (WT33 or WT1) - Pipeline Review, H2 2019

  • Drug Pipelines
  • December 2019
  • 80 Pages
  • Global
From
Blincyto - Product Thumbnail Image

Blincyto

  • Report
  • October 2018
  • 25 Pages
  • Global
From
From
From
From
From
Loading Indicator

Pembrolizumab is a type of oncology drug used to treat certain types of cancer. It is a monoclonal antibody, which works by targeting and blocking a protein called PD-1, which is found on the surface of some cancer cells. This helps the body's immune system to recognize and attack the cancer cells. Pembrolizumab is used to treat a variety of cancers, including melanoma, non-small cell lung cancer, head and neck cancer, Hodgkin lymphoma, and urothelial carcinoma. It is also used in combination with other drugs to treat certain types of advanced or metastatic cancers. Pembrolizumab is approved by the US Food and Drug Administration (FDA) and is available in the US and other countries. It is typically administered intravenously, and the dosage and duration of treatment depend on the type and stage of cancer being treated. Some companies in the Pembrolizumab market include Merck & Co., Inc., Bristol-Myers Squibb, AstraZeneca, and Roche. Show Less Read more